Virus News and Research

Latest Virus News and Research

Mass polio vaccination campaigns in Burma and Sudan

After a seven-month-old baby was diagnosed with polio, Myanmar is planning a mass polio vaccination said the United Nations Children’s Fund. UNICEF revealed that just one case is enough to trigger an “emergency response”, and health officials promptly vaccinated 10,000 children in the Mandalay region, central Myanmar, after the illness was first suspected in December 2010.

23 Feb 2011

Finally! A vaccine against Dengue

Scientists from Thailand have successfully produced the world’s first dengue hemorrhagic fever vaccine and will allow the private sector improve it for the effective treatment of patients. The Thailand Ministry of Science and Technology has introduced the world’s first live attenuated dengue hemorrhagic fever vaccine.

23 Feb 2011

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

23 Feb 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses.

23 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Haiti's cholera outbreak has plateaued, death rate remains high in rural regions, U.N. says

The U.N. on Friday said Haiti's cholera outbreak appears to be waning overall, but high death rates from the virus in rural regions of the country remain a concern, the Associated Press reports. According to figures released by the Haitian government, 231,070 cholera cases and 4,549 deaths from the disease have been reported since the outbreak first emerged in October.

23 Feb 2011

New nanoparticle can help develop vaccines against HIV, malaria

MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

23 Feb 2011

Cancer-causing retrovirus prolongs survival of host cells

A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Ohio State's College of Veterinary Medicine.

23 Feb 2011

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

Health Canada has approved FLUAD, a Novartis seasonal flu vaccine for adults 65 years and older. Canadian seniors are the hardest hit of all age groups by seasonal influenza and account for 90 per cent of influenza deaths and 70 per cent of hospitalizations.

22 Feb 2011

Murray valley encephalitis surfaces after 37 years

A fatal and severe form of mosquito borne viral brain infection has been detected in the Riverina Murray region of New South Wales. Murray Valley encephalitis has affected sentinel chicken flocks in the northern Victorian towns of Mildura, Robinvale, Kerang and Barmah as well in the New South Wales town of Tooleybuc, near Swan Hill. The virus has not been diagnosed in a Victorian for 37 years said Victoria’s Chief Health Officer Dr John Carnie. He said although the virus had not been detected in a human, Victorians living along the Murray River should avoid being bitten by mosquitoes.

22 Feb 2011

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 25, 2010.

22 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

FDA approves OraSure's rapid antibody test to detect HCV

OraSure Technologies, Inc. announced today that its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample.

22 Feb 2011

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda.

21 Feb 2011

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Reoviruses are successfully being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which in turn causes the patient's immune system to attack the disease.

21 Feb 2011

Former President Carter highlights gains in reducing spread of Guinea worm disease

"The global cases of Guinea worm disease have plunged to another new all-time low, former President Jimmy Carter said Thursday, bringing health workers closer to their goal of eradicating the disease," the Canadian Press reports.

19 Feb 2011

Nasal spray vs. injection -- what would you prefer?

Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza.

19 Feb 2011

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.

19 Feb 2011

Virus News and Research

Latest Virus News and Research

Mass polio vaccination campaigns in Burma and Sudan

Finally! A vaccine against Dengue

Multi-national consortium develops new approaches to cure the flu

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Antiepileptic drugs could make HIV drugs less effective

Haiti's cholera outbreak has plateaued, death rate remains high in rural regions, U.N. says

New nanoparticle can help develop vaccines against HIV, malaria

Cancer-causing retrovirus prolongs survival of host cells

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

Murray valley encephalitis surfaces after 37 years

Henry Schein fourth quarter net sales increase 15.1% to $7.5 billion

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

FDA approves OraSure's rapid antibody test to detect HCV

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Sanofi Pasteur, International Vaccine Institute support Dengue Vaccine Initiative

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Former President Carter highlights gains in reducing spread of Guinea worm disease

Nasal spray vs. injection -- what would you prefer?

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in